Baseline characteristics of participants for each subgroup
| IPF | Asbestosis | CTD-ILD | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Usual care n=29 | Exercise training n=32 | p Value | Usual care n=11 | Exercise training n=11 | p Value | Usual care n=12 | Exercise training n=11 | p Value | |
| Age (years) | 73 (9) | 70 (10) | 0.4 | 72 (9) | 72 (7) | 0.1 | 65 (11) | 63 (10) | 0.6 |
| Gender, male | 20 (69%) | 21 (66%) | 0.8 | 11 (100%) | 11 (100%) | 3 (25%) | 1 (9%) | 0.3 | |
| Oxygen therapy | |||||||||
| Long term | 4 (14%) | 2 (6%) | 0.4 | 0 (0%) | 0 (0%) | 1 (8%) | 0 (0%) | 1.0 | |
| Exertional | 10 (35%) | 5 (16%) | 0.1 | 2 (18%) | 0 (0%) | 0.2 | 1 (8%) | 1 (9%) | 1.0 |
| Treatment | |||||||||
| Prednisolone | 10 (35%) | 5 (16%) | 0.1 | 0 (0%) | 0 (0%) | 6 (50%) | 7 (64%) | 0.7 | |
| Immunosuppressant | 3 (10%) | 0 (0%) | 0.1 | 0 (0%) | 0 (0%) | 2 (17%) | 5 (46%) | 0.2 | |
| Pirfenidone | 1 (3%) | 1 (3%) | 1.0 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
| Nintedanib | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | |||
| N-Acetylcysteine | 2 (7%) | 0 (0%) | 0.2 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
| FVC (%pred) | 78 (19) | 74 (18) | 0.4 | 78 (14) | 85 (19) | 0.3 | 71 (26) | 78 (16) | 0.5 |
| TLCO (%pred) | 49 (11) | 50 (17) | 0.1 | 54 (15) | 54 (12) | 1.0 | 51 (14) | 53 (18) | 0.7 |
| TLC (%pred) | 77 (13) | 75 (15) | 0.6 | 80 (17) | 91 (22) | 0.2 | 78 (17) | 82 (19) | 0.7 |
| PASP (mm Hg) | 37 (11) | 35 (16) | 0.4 | 34 (12) | 28 (12) | 0.3 | 30 (10) | 28 (6) | 0.7 |
| 6MWD (m) | 398 (166) | 456 (126) | 0.1 | 498 (113) | 453 (67) | 0.3 | 486 (99) | 526 (74) | 0.3 |
| Knee extensor strength (kg) | 19 (7) | 21 (6) | 0.2 | 24 (7) | 20 (4) | 0.05 | 18 (5) | 20 (5) | 0.5 |
| MMRC dyspnoea | 2 (1) | 2 (1) | 0.3 | 2 (0.7) | 1 (0.5) | 0.5 | 2 (0.7) | 1 (0.4) | 0.04 |
| Total CRDQ score | 83 (23) | 83 (22) | 1.0 | 82 (15) | 90 (21) | 0.3 | 87 (16) | 96 (19) | 0.2 |
| Total SGRQ-I score | 55 (19) | 49 (18) | 0.2 | 53 (17) | 45 (17) | 0.3 | 48 (20) | 41 (16) | 0.1 |
| UCSD SOBQ score | 47 (20) | 39 (23) | 0.2 | 41 (19) | 37 (24) | 0.6 | 43 (25) | 28 (16) | 0.1 |
| HADS anxiety | 6 (4) | 6 (4) | 0.9 | 7 (2) | 6 (4) | 0.4 | 8 (5) | 6 (4) | 0.3 |
| HADS depression | 6 (4) | 5 (3) | 0.2 | 5 (3) | 6 (3) | 0.7 | 6 (3) | 4 (3) | 0.3 |
| Comorbidities | |||||||||
| Hypertension | 11(38%) | 10 (34%) | 0.6 | 6 (55%) | 4 (36%) | 0.7 | 6 (50%) | 2 (18%) | 0.2 |
| Ischaemic heart disease | 8 (28%) | 5 (16%) | 0.4 | 2 (18%) | 5 (46%) | 0.4 | 0 (0%0 | 0 (0%) | |
| Gastro-oesophageal reflux | 3 (10%) | 8 (25%) | 0.2 | 1 (9%) | 0 (0%) | 1.0 | 3 (25%) | 2 (18%) | 1.0 |
| Osteoarthritis | 10 (35%) | 10 (31%) | 1.0 | 3 (27%) | 3 (27%) | 1.0 | 2 (17%) | 2 (18%) | 1.0 |
| Rheumatoid arthritis | 1 (3%) | 1(3%) | 1.0 | 0 (0%) | 0 (0%) | 5 (42%) | 5 (46%) | 1.0 | |
| Diabetes | 10 (35%) | 7 (22%) | 0.4 | 4 (36%) | 3 (27%) | 1.0 | 1 (8%) | 2 (18%) | 0.6 |
| Chronic back pain | 2 (7%) | 3 (9%) | 1.0 | 2 (18%) | 1 (9%) | 1.0 | 2 (17%) | 0 (0%) | 0.5 |
| Obstructive sleep apnoea | 2 (7%) | 4 (13%) | 0.7 | 1 (9%) | 0 (0%) | 1.0 | 0 (0%) | 0 (0%) | |
| COPD | 3 (10%) | 1 (3%) | 0.3 | 0 (0%) | 0 (0%) | 1 (8%) | 0 (0%) | 1.0 | |
| Osteoporosis | 2 (7%) | 1 (3%) | 0.6 | 0 (0%) | 0 (0%) | 1 (8%) | 1 (9%) | 1.0 | |
Values are mean (SD) or n (%).
6MWD, six-minute walk distance; %pred, per cent predicted; CRDQ, Chronic Respiratory Disease Questionnaire; CTD, connective tissue disease; HADS, Hospital Anxiety and Depression Scale; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; MMRC, Modified Medical Research Council; PASP, pulmonary artery systolic pressure; SGRQ-I, St George Respiratory Questionnaire IPF specific version; TLC, total lung capacity; TLCO, carbon monoxide transfer factor; UCSD SOBQ, University College of San Diego Shortness of Breath Questionnaire.